Cargando…

Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody

The pancaner molecule CD276 (B7-H3) is an attractive target for antibody based therapy. We identified from a large (10(11)) phage-displayed single-chain variable fragment (scFv) library, a fully human antibody, B11, which bound with high avidity (K(D)=0.4 nM) to CD276. B11 specifically bound to the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xianglei, Zhelev, Doncho, Adams, Cynthia, Chen, Chuan, Mellors, John W, Dimitrov, Dimiter S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493583/ https://www.ncbi.nlm.nih.gov/pubmed/34601396 http://dx.doi.org/10.1016/j.tranon.2021.101232

Ejemplares similares

Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates
por: Kim, Ye-Jin, et al.
Publicado: (2023)

Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization
por: Buongervino, Samantha, et al.
Publicado: (2021)

Bispecific T cell engager (BiTE(®)) antibody constructs can mediate bystander tumor cell killing
por: Ross, Sandra L., et al.
Publicado: (2017)

Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody
por: Ahmed, Mahiuddin, et al.
Publicado: (2015)

Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice
por: Liu, Xianglei, et al.
Publicado: (2020)

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies
por: Zitron, Ian M, et al.
Publicado: (2013)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
por: Osada, T, et al.
Publicado: (2010)

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
por: Hambach, Julia, et al.
Publicado: (2022)

Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
por: Moon, Dain, et al.
Publicado: (2022)

Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies
por: Chen, Jie, et al.
Publicado: (2023)

Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy
por: Song, Xinxin, et al.
Publicado: (2022)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

Novel Human Bispecific Aptamer–Antibody Conjugates for Efficient Cancer Cell Killing
por: Passariello, Margherita, et al.
Publicado: (2019)

Bispecific Engineered Antibody Domains (Nanoantibodies) That Interact Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn
por: Gong, Rui, et al.
Publicado: (2012)

Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection
por: Li, Wei, et al.
Publicado: (2020)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
por: Fu, Mingpeng, et al.
Publicado: (2019)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
por: Poussin, Mathilde, et al.
Publicado: (2021)

Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo
por: Zhong, Liping, et al.
Publicado: (2021)

One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells
por: Li, Wei, et al.
Publicado: (2017)

Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
por: Trinklein, Nathan D., et al.
Publicado: (2019)

A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells
por: Lund, Maria E., et al.
Publicado: (2020)

Protocol for constructing large size human antibody heavy chain variable domain (V(H)) library and selection of SARS-CoV-2 neutralizing antibody domains
por: Chen, Chuan, et al.
Publicado: (2021)

In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
por: Kruse, Robert L., et al.
Publicado: (2017)

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
por: Dang, Kevin, et al.
Publicado: (2021)

Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
por: Yuraszeck, T, et al.
Publicado: (2017)

Correction: Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
Publicado: (2021)

Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies
por: Loh, Han Ping, et al.
Publicado: (2023)

GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody
por: Gedeon, Patrick C., et al.
Publicado: (2020)

Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody
por: Wang, Lei, et al.
Publicado: (2013)

Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22
por: Sun, Zehua, et al.
Publicado: (2022)

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
por: Jitschin, Regina, et al.
Publicado: (2018)

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
por: Caracciolo, Daniele, et al.
Publicado: (2021)

Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells
por: Herrmann, Ines, et al.
Publicado: (2010)

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
por: Wu, Jingjing, et al.
Publicado: (2015)

Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models
por: Warwas, Karsten M., et al.
Publicado: (2021)

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells
por: Lutz, Sebastian, et al.
Publicado: (2023)

Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate
por: Sun, Zehua, et al.
Publicado: (2023)

The landscape of bispecific T cell engager in cancer treatment
por: Zhou, Shujie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pbiv6bq54aslj83i02m5ol8ppf